Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 175

1.

Dealing with the unexpected: consumer responses to direct-access BRCA mutation testing.

Francke U, Dijamco C, Kiefer AK, Eriksson N, Moiseff B, Tung JY, Mountain JL.

PeerJ. 2013 Feb 12;1:e8. doi: 10.7717/peerj.8. Print 2013.

PMID:
23638402
[PubMed]
Free PMC Article
2.

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation [Internet].

Nelson HD, Fu R, Goddard K, Mitchell JP, Okinaka-Hu L, Pappas M, Zakher B.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Dec.

3.

Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility [Internet].

Nelson HD, Huffman LH, Fu R, Harris EL, Walker M, Bougatsos C.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Sep.

4.

Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.

Tobias DH, Eng C, McCurdy LD, Kalir T, Mandelli J, Dottino PR, Cohen CJ.

Gynecol Oncol. 2000 Aug;78(2):148-51.

PMID:
10926794
[PubMed - indexed for MEDLINE]
5.
6.

Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.

Lavie O, Narod S, Lejbkowicz F, Dishon S, Goldberg Y, Gemer O, Rennert G.

Ann Oncol. 2011 Apr;22(4):964-6. doi: 10.1093/annonc/mdq460. Epub 2010 Oct 5.

PMID:
20924075
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.

Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA.

Am J Hum Genet. 2000 Apr;66(4):1259-72. Epub 2000 Mar 16.

PMID:
10739756
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

PMID:
17109443
[PubMed - indexed for MEDLINE]
Free Article
9.

Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.

Hodgson SV, Heap E, Cameron J, Ellis D, Mathew CG, Eeles RA, Solomon E, Lewis CM.

J Med Genet. 1999 May;36(5):369-73.

PMID:
10353781
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.

Roa BB, Boyd AA, Volcik K, Richards CS.

Nat Genet. 1996 Oct;14(2):185-7.

PMID:
8841191
[PubMed - indexed for MEDLINE]
11.

Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.

Botkin JR, Smith KR, Croyle RT, Baty BJ, Wylie JE, Dutson D, Chan A, Hamann HA, Lerman C, McDonald J, Venne V, Ward JH, Lyon E.

Am J Med Genet A. 2003 Apr 30;118A(3):201-9.

PMID:
12673648
[PubMed - indexed for MEDLINE]
12.

Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel.

Rennert G, Dishon S, Rennert HS, Fares F.

Eur J Cancer Prev. 2005 Aug;14(4):357-61.

PMID:
16030426
[PubMed - indexed for MEDLINE]
13.

The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.

Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T.

Am J Hum Genet. 1997 Mar;60(3):505-14.

PMID:
9042909
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

BRCA genetic testing of individuals from families with low prevalence of cancer: experiences of carriers and implications for population screening.

Shkedi-Rafid S, Gabai-Kapara E, Grinshpun-Cohen J, Levy-Lahad E.

Genet Med. 2012 Jul;14(7):688-94.

PMID:
22481128
[PubMed - indexed for MEDLINE]
15.

Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.

Robson M, Dabney MK, Rosenthal G, Ludwig S, Seltzer MH, Gilewski T, Haas B, Osborne M, Norton L, Gilbert F, Offit K.

Genet Test. 1997;1(1):47-51.

PMID:
10464625
[PubMed - indexed for MEDLINE]
16.

The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB.

Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):467-73.

PMID:
11352856
[PubMed - indexed for MEDLINE]
Free Article
17.

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.

Clin Cancer Res. 2002 Dec;8(12):3776-81.

PMID:
12473589
[PubMed - indexed for MEDLINE]
Free Article
18.

An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews.

Lalloo F, Cochrane S, Bulman B, Varley J, Elles R, Howell A, Evans DG.

J Med Genet. 1998 Jan;35(1):10-2.

PMID:
9475087
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients.

Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST, Eng CM.

Am J Hum Genet. 1998 Jul;63(1):45-51.

PMID:
9634504
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.

Lehrer S, Fodor F, Stock RG, Stone NN, Eng C, Song HK, McGovern M.

Br J Cancer. 1998 Sep;78(6):771-3.

PMID:
9743298
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk